SCHEMBL5540611

SCHEMBL5540611

O=CCCN1CCN(C(=O)OCc2ccccc2Cl)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.57
F13A1 P00488 1/20 0.50
TGM2 P21980 1/20 0.50
TGM1 P22735 1/20 0.50
FNTA P49354 1/20 0.48
FNTB P49356 1/20 0.48
PGGT1B P53609 1/20 0.48
MAPT P10636 2/20 0.46
ENPP2 Q13822 1/20 0.45
KCNH2 Q12809 1/20 0.43
KDM4E B2RXH2 1/20 0.43
POLB P06746 1/20 0.43
ALOX15 P16050 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
FAAH O00519 1/20 0.42
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
RAB9A P51151 1/20 0.41
KCNA5 P22460 1/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5542023 0.93 ALDH1A1 (0.55) ALDH1A1F13A1TGM2TGM1FNTA
SCHEMBL5544501 0.92 ALDH1A1 (0.54) ALDH1A1F13A1TGM2TGM1FNTA
SCHEMBL5537545 0.85 ALDH1A1 (0.57) ALDH1A1F13A1TGM2TGM1ENPP2
SCHEMBL5539413 0.85 ALDH1A1 (0.60) ALDH1A1F13A1TGM2TGM1FNTA
SCHEMBL5547878 0.83 ALDH1A1 (0.57) ALDH1A1F13A1TGM2TGM1FNTA
SCHEMBL5540605 0.83 ALDH1A1 (0.57) ALDH1A1F13A1TGM2TGM1FNTA
SCHEMBL5536676 0.82 F13A1 (0.52) ALDH1A1F13A1TGM2TGM1MAPT
SCHEMBL5537966 0.82 MEN1 (0.57) F13A1TGM2TGM1ENPP2KMT2A
SCHEMBL27629430 0.82 ALDH1A1 (0.56) ALDH1A1F13A1TGM2TGM1FNTA
SCHEMBL5542019 0.81 ALDH1A1 (0.55) ALDH1A1F13A1TGM2TGM1FNTA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ALDH1A1 355/4885F13A1 3793/4885TGM2 3103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.